MAR 0 3 2003



PATENT

Our Docket: P-LJ 5037

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

)

)

MAR 0 5 2003

In re Application of:

Reed et al.

Serial No.: 10/001,254

Filed: November 15, 2001

For: NOVEL DEATH DOMAIN

PROTEINS

Commissioner for Patents Washington, D.C. 20231

Group Art Unit: 1642

TECH CENTER 1600/291 Examiner: Not yet known

I hereby certify that this correspondence is being deposited with the United States

Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington,

D.C. 20231, on February 24, 2003:

February 24, 2003 Date of Signature

## INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97(d), enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449.

I hereby state under 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

No fees are deemed necessary in connection with the filing of this Information Disclosure Statement. However, if a fee is required, the Commissioner is hereby authorized to charge payment of this fee to Deposit Account No. 03-0370.

Inventors:
Serial No.:

Reed et al. 10/001,254

Filed:

November 15, 2001

Page 2

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

Respectfully submitted,

Deborah L. Cadena

Registration No. 44,048 Telephone: (858) 535-9001 Facsimile: (858) 535-8949

CAMPBELL & FLORES LLP 4370 La Jolla Village Drive 7<sup>th</sup> Floor San Diego, California 92122 USPTO CUSTOMER NO. 23601

Form PTO 14490 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: SERIAL NO. 10/001,254		
	APPLICANT: Reed et al.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: November 15, 2001	GROUP: 1642	

## U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS	EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
20U3						256	EIVED
COUNTER 160012							00114 II
FOREIGN PATENT DOCUMENTS	<u>_</u>		FORETCN PA	TENT DOCUMEN	IT'S	CU (	ENTER 1600/29

	 · · · · · · · · · · · · · · · · · · ·				15/1/	<u> </u>
EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	WO 95/10630	4/20/95	PCT			
	 WO 97/00690	1/9/97	PCT			
	WO 98/39429	9/11/98	PCT			
	 WO 99/27112	6/3/99	PCT			
	WO00/20587	4/13/00	PCT	<u> </u>		
	WO 01/51641 (original and corrected verison)	7/19/01	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			Page 2 of 2
Form PTO 1449 US Department of Commerce Patent and Trademark Office		ATTY DOCKET NO: P-LJ 5037	SERIAL NO.
		APPLICANT: John C. Reed	
INFORMATION DI STATEMENT BY A		FILING DATE: November 15, 2001	GROUP:

	Genbank Accession No. Q9Y589
	Genbank Accession No. AK000528
	Genbank Accession No. Q9NWZ3
	Kanakaraj et al., "Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production," <u>J. Exp. Med.</u> 187:2073-2079 (1998)
	Kissil et al., "Isolation of DAP3, a novel mediator of interferon- $\gamma$ -induced cell death," <u>J. Biol. Chem.</u> 270:27932-27936 (1995)
	Stegh et al., "DEDD, a novel death effector domain-containing protein, targeted to the nucleous," <a href="MBO J.">EMBO J.</a> 17:5974-5986 (1998)
	van der Biezen and Jones, "The NB-ARC domain: a novel signalling motif shared by plant resistance gene products and regulators of cell death in animals," Current Biol. 8:226-227 (1998)
	Wesche et al., "IRAK-M is a novel member of the pelle/interleukin-1 receptor-associated kinase (IRAK) family," <u>J. Biol. Chem.</u> 274:19403-19410 (1999)
_	

EXAMINER	DATE CONSIDERED
·	·

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.